[Xinhua Pharmaceutical: Subsidiary obtains drug registration certificate for donepezil hydrochloride orally disintegrating tablets] On September 20, Xinhua Pharmaceutical (000756.SZ) announced that the company's wholly-owned subsidiary Xinda Pharmaceutical has received the "Drug Registration Certificate" for donepezil hydrochloride orally disintegrating tablets approved and issued by the State Food and Drug Administration. This drug is used to treat mild, moderate or severe symptoms of Alzheimer's disease and belongs to Category B of the National Medical Insurance. In 2025, the sales of donepezil preparations in China's public medical institutions will be approximately 620 million yuan. This approval will help enrich the company's product series in the central nervous system field and enhance overall competitiveness.